Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-23

FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp)

View source ↗

Summary

FDA approved a supplemental application for ibandronate sodium submitted by Apotex Corp as part of an ANDA, representing a regulatory update to the generic drug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)